Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

BioDelivery's Big Quarter

|About: BioDelivery Sciences International, Inc. (BDSI)

Nobody’s ever been arrested for a murder; they have only ever been arrested for not planning it properly.”― Terry Hayes, I Am Pilgrim

We continue our series of reviews of Q2 results at previously profiled small biotech concerns today.  In today's post we revisit BioDelivery Sciences (BDSI) Q2 results that showed impressive revenue growth that was significantly over expectations.  The company remains on track to produce positive cash flow by year end and seems undervalued in this skittish market.

Company Overview:

Image result for Belbuca Sciences is a North Carolina based specialty pharmaceutical company focused.  The firm is focused on pain management.   The company's main product is BELBUCA whose main ingredient is Buprenorphine. This product is for pain management and has a relatively low risk for developing dependence. This product's impressive growth is a product of the country's increasing focus on its opioid crisis and the need to find less addictive pain management solutions. The stock currently has a market capitalization of approximately $390 million and trades right around $4.30 a share. 

Quarterly Highlights:

The company posted a loss of 13 cents a share, a dime a share below than the consensus.   It should be noted that BioDelivery had EBITDA in the second quarter of 2019 of $4.8 million or 16.1% of total net revenue.  This compares with $0.1 million in the first quarter of 2019 and ($5.6) million in the second quarter of 2018.  Non-GAAP net income for the quarter was a positive $4.4 million.

Revenue growth was very impressive as the company posted sales of $29.7 million, up 144% from the year ago period and above expectations.

Image result for Symproic BELBUCA accounted for $24.1 million of that total.   Newly acquired Symproic® had an impressive launch in the hands of BioDelivery and posted $3.2 million in revenues during the second quarter.

The company raised forward guidance across the board as well.  BioDelivery now expects net sales in FY2019 to come in within a range of $101 - $105 million, from the previous level of $92 – $100 million.    The company also raised its long-term combined net sales expectations for BELBUCA and Symproic to a range of $425 million - $500 million 

Analyst Commentary & Balance Sheet:

The current median analyst price target is just over $6.00 a share.  H.C. Wainwright reissued their Buy rating and $6.50 price target on BDSI Friday with this brief commentary on valuation.

We maintain a conservative view on Symproic—far below the long-term $75-100M target—until the company shows it can drive material volume and share growth. We think it’s a best-in-class product, but the space remains competitive."

The company ended the second quarter with just over $55 million in cash and marketable securities on the balance sheet.  More importantly, management anticipates having positive operating cash flow by the fourth quarter of 2019; and important milestone, obviously. 


The company continues to show impressive growth in BELBUCA scripts and sales.  Recently acquired Symproic also seems to be off to a good start in the hand of BioDelivery as well.  The company is on its way to achieving cash flow positive status by the close of this year.  Selling at less than one times the eventual annual sales management believes it can achieve with BELBUCA and Symprioc, the shares remain cheap.

Option Strategy:

Image result for Stock Purchase

An efficient way to add exposure or initiate a new position in BDSI is via a Buy-Write order. Using the March $5 call strikes, fashion a Buy-Write order with a net debit in the $3.70 to $3.80 range (net stock price - option premium). This mitigates a bit of downside risk and sets up a solid potential return for its just over seven month hold period.

Nothing gives a fearful man more courage than another's fear.” ― Umberto Eco, The Name of the Rose

Tim Plaehn of The Dividend Hunter just published a new free report covering three cheap dividend stocks he likes right now and that should be long term holdings in 401Ks and retirement accounts. The new research can be downloaded free HERE.

These include:

  • A real estate powerhouse that has doubled their dividend payout in just 5 years
  • A double-digit yield (13%) energy company that’s trading at a 66% discount
  • Tim's $6 ‘no-brainer’ play that sends you monthly dividend checks

Thank You & Happy Hunting,

Bret Jensen

Founder, The Biotech Forum, The Busted IPO Forum & The Insiders Forum

Disclosure: I am/we are long bdsi.